Johnson & Johnson
09/27/2024 | Press release | Distributed by Public on 09/27/2024 14:32
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
Sharing and Personal Tools
Please select the service you want to use:
Smartlinks | Johnson & Johnson | News | Health | Securities Issuers | Pharmaceutical Companies | Borsa Italiana | London Stock Exchange (LSE) | New York Stock Exchange (NYSE) | Frankfurt Stock Exchange | Six Swiss Exchange | Sao Paulo Stock Exchange (B3) | Vienna Stock Exchange (ATX) | Berlin Stock Exchange | Dusseldorf Stock Exchange | Hamburg Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Santiago Stock Exchange | Bolsa Mexicana de Valores (BMV) | Buenos Aires Stock Exchange (BCBA) | Lima Stock Exchange (BVL) | Moscow Exchange (MOEX) | PFTS Ukraine Stock Exchange | Colombia Securities Exchange | Kazakhstan Stock Exchange (KASE) | Bulgarian Stock Exchange | BX Swiss | Ukrainian Exchange | Tradegate Exchange | XETRA | NYSE American | NYSE ARCA Equities | Bolsa Electrónica de Chile | Cboe Canada | Cboe BZX Exchange | Cboe BXE Europe | Cboe CXE Europe | Cboe Off Exchange | Cboe BYX Exchange | Cboe EDGA Exchange | Cboe EDGX Exchange | NYSE National | FINRA Alternative Display Facility (ADF) | Aquis Exchange | Investors Exchange (IEX) | Omega ATS | Lynx ATS | SIGMA X MTF | EuroTLX | Bolsa Institucional de Valores (BIVA) | Aquis Exchange Europe | Equiduct | Hannover Stock Exchange | Nasdaq BX | Nasdaq CX2 | Nasdaq CXC | Nasdaq Intermarket | Nasdaq PSX | NYSE Chicago | Turquoise
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact